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Abstract To investigate if neurotensin (NT) could induce 
activation of urokinase-type plasminogen activator (uPA) in 
vascular endothelial cells, we utilized the acetyl-NT (8-13) 
analogue, T JN-950, in which the C-terminal leucine is reduced to 
leucinol. TJN-950 inhibited the binding of 125I-NT to membranes 
of newborn rat brains and of COS-7 cells transfected with rat 
NT receptor cDNA, but at 104 higher doses than NT (8-13). 
However, TJN-950 was as effective as NT in inducing the 
fibrinolytic activity in bovine vascular aortic and human 
umbilical vein endothelial cells, and enhanced the migration of 
vascular endothelial cells. Moreover, administration of TJN-950 
induced neovascularization in the rat cornea in vivo. TJN-950 
had no effect on expression of uPA, plasminogen activator 
inhibitor-1 or uPA receptor mRNA. The binding of 125I-TJN-
950 to cell membranes was blocked by unlabeled uPA and TJN-
950, but not the amino-terminal or 12-32 fragment of uPA. 
TJN-950 may enhance uPA activity in vascular endothelial cells 
by interacting with the uPA receptor, resulting in induction of 
angiogenesis. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Neurotensin (NT) is a tridecapeptide that was originally 
isolated from extracts of the bovine hypothalamus [1,2]. In 
mammals , N T is widely distributed throughout the central 
nervous system and digestive tract [3,4]. The biological activ-
ities have been shown to reside in the carboxy-terminal hexa-
peptide of N T [5]. N T has been found to interact with at least 
*Corresponding author. Fax: (81) (92) 632-4198. 
Abbreviations: acetyl-NT (8-13), JV-acetylated neurotensin fragment 
(8-13); ATF, amino-terminal fragment of uPA; BAE, bovine aortic 
endothelial; bFGF, basic fibroblast growth factor; DMEM, Dulbec-
co's modified Eagle medium; FBS, fetal bovine serum; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; HUVE, human umbilical 
vein endothelial; NT, neurotensin; NTR1 and NTR2, neurotensin 
receptor 1 and 2; NT (8-13), neurotensin fragment (8-13); PA, 
plasminogen activator; PAI-1, plasminogen activator inhibitor-1; PBS, 
phosphate-buffered saline; SDS-PAGE, sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis; uPA, urokinase-type plasminogen 
activator; uPAR, urokinase-type plasminogen activator receptor 
two specific membrane receptors. The high affinity receptor, 
N T R 1 , is expressed in the brain, intestine and blood mono-
nuclear cells, whereas the low affinity, levocavastine sensitive 
receptor, N T R 2 , is expressed in brain and heart [6]. Binding 
of N T to its high affinity receptors has been reported to be 
coupled to intracellular calcium release [7]. 
N T and its acetylated fragment, acetyl-NT (8-13), showed 
dual activities of decreasing blood pressure and inhibiting 
vascular leakage/edema formation in peripheral tissues [8-
10], but these activities were mediated through independent 
pathways [11]. We produced a novel analogue of ,/V-acetyl-
N T hexapeptide, TJN-950 whose C-terminal leucine is re-
duced, inhibiting the ability of this peptide to bind to the 
N T receptor, and we found that TJN-950 showed a specific 
inhibition of vascular permeability without any effect on 
blood pressure (unpublished data). To investigate whether 
TJN-950 could modulate uPA activities in vascular endothe-
lial cells, we have now examined the effects of TJN-950 on the 
activation of uPA, on the migration of human and bovine 
vascular endothelial cells, as well as on the angiogenesis in 
the rat cornea. 
2. Materials and methods 
2.1. Materials 
TJN-950 is a hexapeptide analogue of JV-acetyl-NT (8-13) whose 
C-terminal leucine is reduced to leucinol. This analogue was supplied 
by Tsumura Co., Ltd. (Tokyo, Japan). NT was purchased from Pep-
tide Institute, Inc. (Osaka, Japan). Mono[125]iodo[Tyr3]NT (1251-NT; 
200 mCi/mmol) was prepared by McFarlane's procedure. Human high 
molecular weight uPA and ATF were purchased from American Di-
agnostica, Inc. (Greenwich, USA). Human uPA [12-32(Ala19)] [12] 
was synthesized by the Peptide Institute, Inc. (Osaka, Japan). 
All other chemicals were obtained from commercial sources. 
2.2. Iodination of TJN-950 
To iodinate TJN-950, 1 ug of this substance was dissolved in 10 ul 
of 400 mM sodium acetate buffer (pH 5.6) and 2 fj.1 of iodine-125 
(100 mCi/ml; Amersham, Tokyo, Japan) and 5 ul of lactoperoxidase 
(83.3 ug/ml) were added. Three 5 ul aliquots of 0.003% H2O2 were 
added at 5 min intervals. Iodination was terminated by the addition of 
35% acetonitrile containing 0.1% trifluoroacetic acid. The mixture was 
injected onto a TSK gel ODS-80 column (4.6 mmXl5 cm, Tosoh 
Corp., Tokyo, Japan) and purified by HPLC using a mobile phase 
of 20% acetonitrile, 0.1%o trifluoroacetic acid and monitoring with a 
UV detector coupled to a gamma counter. Fractions counting radio-
activity were collected, frozen and dried, and the iodinated peptide 
was reconstituted in 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 2 mM 
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MgS04, 10 uM 1,10-phenanthroline. Specific radioactivity was calcu-
lated from spectrophotometric and radioactivity measurements. 
2.3. Cell culture 
BAE cells isolated from bovine aortas [13,14] were cultured in 
DMEM (Nissui, Tokyo) supplemented with 10% FBS, 100 U/ml pen-
icillin, and 60 ug/ml kanamycin. HUVE cells (Kurabou Co., Osaka, 
Japan) were cultured in the appropriate medium. 
BAE cells were homogenized by suspending 5 X 109 cells in 10 vol-
umes 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 2 mM MgS04, 
0.002% soybean trypsin inhibitor, 10 U.M leupeptin, 10 uM aprotinin 
in a teflon-glass homogenizer. The membrane fraction was prepared 
by centrifugation, its protein concentration was measured [15], and it 
was stored at —80°C. Whole brain homogenate from 7-day-old rats 
was prepared as described [16]. 
2.4. Transfection of COS-7 cells 
The HindlU-NotI fragment encoding rat NTR1 [17] was ligated 
into the HindlU-NotI cloning site of the CDM8 vector and trans-
fected into COS-7 cells by the DEAE-dextran precipitation method. 
Membrane fractions were prepared 48-72 h after transfection as de-
scribed above. 
2.5. Binding assay 
The binding of 125I-NT to membranes of newborn rat brains and 
COS-7 cells was performed at 26°C in 50 mM Tris-HCl buffer (pH 
7.5) containing 0.2% bovine serum albumin and 1 mM 1,10-phenan-
throline in the presence of 0.05-0.10 nM 126I-NT. Binding of 125I-
TJN-950 to BAE cell membranes was performed at 20°C in 50 mM 
Tris-HCl (pH 7.5), 1 mM EGTA, 2 mM MgS04, 10 uM 1,10-phe-
nanthroline, and 0.3 nM 125I-TJN-950. Total, non-specific, and spe-
cific binding were measured at equilibrium by the filtration technique 
[18]. 
2.6. Cell migration assay and fibrin zymography 
The cell migration assay and fibrin zymography were performed as 
described previously [14,19]. 
2.7. Northern blot analysis 
Northern blot analysis was performed as described [20]. Total RNA 
was isolated, separated by electrophoresis in 1% agarose, 2.2 M form-
aldehyde gels and blotted onto Hybond-N+ (Amersham) membranes. 
The membranes were hybridized with 32P-labeled mouse uPA cDNA 
[14], bovine PAI-1 cDNA [21] and human uPA receptor (uPAR) 
cDNA (the kind gift of K. Matsuo, Taiho Research Center) probes, 
and then with a human GAPDH probe (Japanese Cancer Research 
Resource Bank). Hybridization was visualized by autoradiography, 
and densitometric analysis was performed using a BAS 2000 Fujix 
imaging analyzer (Fujix, Tokyo). 
2.8. Cornea! pocket assay 
The corneal assay was performed essentially as described [22]. 
Briefly, 5 ul hydron pellets (Interferon Sciences, New Brunswick, 
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Fig. 1. Binding characteristics of TJN-950 and NT (8-13) for high 
affinity rat NT receptors. A: Membranes from newborn rat brains. 
B: Membranes from COS-7 cells transfected with high affinity rat 
NTR (NTR1) cDNA. Binding of 125I-NT was performed in the ab-
sence or presence of TJN-950 (•) or NT (8-13) (o). Each value is 
the mean of three independent experiments. 
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Fig. 2. Effects of TJN-950 on uPA activity. Confluent monolayers 
were incubated in DMEM containing 10% FBS with increasing 
doses of TJN-950 for 24 h. For fibrin zymography, cell homoge-
nates or culture media were separated by non-reducing SDS-PAGE 
and transferred to fibrin-agar indicator gels. A: uPA activity in cell 
lysate (upper panel) and medium (lower panel) of BAE cells. Trans-
parent bands had an apparent molecular weight of 52 kDa, consis-
tent with that of bovine uPA. B: uPA activity in cell lysates of 
HUVE cells; the band had an apparent molecular weight of 54 
kDa, consistent with that of human uPA. C: BAE cells treated with 
100 itM TJN-950, NT or both for 24 h. D: Effect of TJN-950 on 
uPA secreted into conditioned medium of BAE cells (upper panel) 
and on purified uPA (lower panel). 
NJ) containing 250 nmol TJN-950 were implanted into the cornea 
of anesthetized rats. After 7 days, the animals were killed, and corneal 
vessels were photographed. Six rats were used to asses the effect of 
TJN-950. 
3. Results and discussion 
We compared the ability of TJN-950 and N T (8-13) to 
compete with the binding of 1 2 5I-NT to N T receptors in two 
assay systems: the membrane fractions prepared from new-
born rat brains (Fig. 1A) and the membrane fraction of rat 
N T R 1 cDNA-transfected COS-7 cells (Fig. IB). At a concen-
tration of 10~9 M, N T (8-13) showed almost complete inhi-
bition of 1 2 5I-NT binding in bo th assay systems (Fig. 1), and 
the inhibitory kinetics for N T (8-13) were almost identical to 
those for non-radioactive N T (data not shown). In contrast, 
TJN-950 was less effective at inhibiting the binding of 1 2 5 I -
N T , showing 104-fold lower affinity for the N T R 1 than N T 
(8-13) (Fig. 1). F rom the dose-response kinetics the IC50 in 
newborn rat brains was 2.1 X l O - 6 M for TJN-950 and 
6.8 X 10"1 1 M for N T (8-13) (Fig. 1A); in COS-7 cells trans-
fected with N T R 1 cDNA, the IC 5 0 was 7.7 X 10"
7 M for TJN-
950 and 7.1 X 1 0 " 1 1 M for N T (8-13) (Fig. IB). 
Utilizing fibrin zymographic analysis, we next examined 
whether TJN-950 could modulate PA in vascular endothelial 
cells. Treatment of BAE cells for 24 h with 10-1000 u M TJN-
950 induced a dramatic increase in u P A activity in bo th cell 
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Fig. 3. Effect of TJN-950 on endothelial cell migration in vitro. 
Confluent monolayers of BAE cells were scraped with a razor blade, 
and incubated for 24 h in DMEM supplemented with 1% FBS and 
10 ng/ml bFGF or 1-100 mM TJN-950. The number of migrating 
cells was counted in successive 100-mm sections from the denuded 
edge in four random fields (1000 X 1000 mm2 per field ). * Significant 
difference (P<0.01) compared to control. 
lysates and medium (Fig. 2A). In contrast, reverse zymo-
graphic analysis showed no change in 45 kDa PAI-1 activity 
(data not shown). TJN-950 also enhanced uPA activity in 
HUVE cells in a dose-dependent manner (Fig. 2B). In BAE 
cells, similar levels of PA activity were induced by 100 uM 
TJN-950 and 100 |j.M NT, and co-administration of both 
reagents did not further enhance uPA activity (Fig. 2C), sug-
gesting that the induction of uPA activity by TJN-950 and NT 
occur via a similar pathway. To determine if TJN-950 can 
directly activate uPA, we added TJN-950 to the conditioned 
medium of BAE cells or to purified uPA (Fig. 2D). TJN-950 
had no effect on uPA activity in either case, indicating that the 
TJN-950-induced uPA activation is not due to a direct inter-
action. 
Migration of vascular endothelial cells is closely associated 
with their PA activity [23,24]. We therefore assayed the ability 
of TJN-950 to enhance the migration of BAE cells. Treatment 
with 1, 10 and 100 uM TJN-950 significantly stimulated the 
migration of BAE cells (Fig. 3). As a comparison, the positive 
control, 10 ng/ml bFGF, stimulated a 3-fold enhancement of 
cell migration (Fig. 3). TJN-950-induced enhancement of cell 
migration was almost completely blocked by co-administra-
tion of anti-uPA antibody (data not shown), suggesting the 
involvement of uPA in TJN-950-induced cell migration. 
To examine if TJN-950 could induce angiogenesis in vivo, 
we implanted hydron pellets impregnated with TJN-950 into 
rat corneas. TJN-950 (250 nmol) elicited an angiogenic re-
sponse, but administration of PBS alone did not (Fig. 4). 
TJN-950 could thus induce angiogenesis in the in vivo model 
system. 
We next determined whether TJN-950-induced activation of 
uPA is due to enhanced expression of uPA-encoded mRNA. 
Treatment of BAE cells for 24 h with 100 uM TJN-950 in-
duced no change in the levels of uPA and PAI-1 mRNA (Fig. 
5A). TJN-950 had no effect on uPA, PAI and uPAR mRNA 
expression in HUVE cells (Fig. 5B). Thus, it appeared that 
TJN-950-induced activation of uPA was not due to an up-
regulation of uPA and uPAR genes expression or to a down-
regulation of PAI-1 gene expression. 
Concomitant binding of pro-uPA or latent uPA to uPAR 
Fig. 4. The effect of TJN-950 on in vivo angiogenesis in rat cornea. 
Hydron pellets were formulated as described in Section 2 and im-
planted into rat corneas. Seven days later vessels in the region of 
the pellet implant were photographed. Pellets contained (A) PBS 
and (B) TJN-950. 
has been shown to induce preferential and effective activation 
of uPA [25]. We therefore assayed the binding of 125I-TJN-950 
to BAE cell membranes in the presence of various doses of 
TJN-950 or purified uPA (Fig. 6A). Almost identical compe-
tition kinetics were observed for TJN-950 and the uPA prep-
aration, suggesting that they have similar binding sites on 
vascular endothelial cell membranes. To further examine 
whether TJN-950 directly interacted with uPAR, we assayed 
the binding of 125I-TJN-950 to BAE cell membranes in the 
presence of uPA peptides essential for its binding to uPAR. 
B 
Sn.&*i 
uPA — 
PAI-1 — m 
uPA — 
PAI-1 II 
GAPDH — 
TJN-950(nM) 100 
UPAR — 
GAPDH — 
TJN-950(uM|l 100 
Fig. 5. Effect of TJN-950 on expression of uPA, PAI-1 and uPAR 
mRNA in vascular endothelial cells. BAE (A) or HUVE (B) cells 
were incubated with 100 mM TJN-950 for 24 h, and their total 
RNAs were extracted and assayed for expression of uPA, PAI-1 
and uPAR message. As a control, levels of GAPDH mRNA were 
also determined. 
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NT analogue, TJN-950, which may activate uPA activity 
though its interaction with uPAR on vascular endothelial 
cells, may thus be useful in the treatment of such disorders 
that involve uPA. 
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Fig. 6. Competitive assay for 125I-TJN-950 binding to BAE cell 
membranes. A: Membranes incubated with 125I-TJN-950 and indi-
cated concentrations of non-radioactive TJN-950 (o) or uPA (•). 
B: Membranes incubated with 125I-TJN-950 and indicated concen-
trations of non-radioactive TJN-950 (n), ATF (•) or uPA [12-
32(Ala19)] (■). Each value is the mean of three duplicate experi-
ments. 
Exogenous administration of ATF (up to 10~4 M) or uPA 
[12-32(Ala19)] (up to 10"5 M) did not appreciably inhibit 
125I-TJN-950 binding, however. In contrast, 10~5 M 
TJN-950 inhibited binding by almost 80% (Fig. 6B). 
In this study, we utilized a novel analogue of acetyl-NT (8-
13), TJN-950, to investigate the effects of NT on vascular 
endothelial cells. Although TJN-950 induced the activation 
of uPA in these cells, it did not do so by increasing expression 
of uPA- and uPAR-encoded mRNA, or by decreasing the 
expression of PAI-1-encoded message. These results suggest 
that the mechanism of NT-induced uPA activation may not 
occur at the transcriptional level. TJN-950 lost its affinity to 
NTR1 which NT or acetyl-NT (8-13) binds. TJN-950, how-
ever, showed similar affinity to uPAR as NT. Activation of 
uPA by TJN-950 thus appeared to be mediated through its 
interaction with uPAR. However, the precise mechanism of 
how TJN-950 or NT interacts with uPAR remains unclear at 
present. 
The PA-plasmin system is required for the migration of 
vascular endothelial cell and tubular morphogenesis (angio-
genesis) [23,24]. Inhibition of PA by irsogladine or nortriter-
penoid has been shown to result in the inhibition both of cell 
migration and of angiogenesis in vitro as well as in vivo 
[20,26,27]. These results suggest that activation of the PA-
plasmin system in vascular endothelial cells is closely coupled 
to cell migration and angiogenesis. We have shown here that 
the NT analogue, TJN-950, also enhanced vascular endothe-
lial cell migration, providing further evidence that these two 
activities may be coupled. Moreover, administration of TJN-
950 resulted in a potent angiogenic response in rat cornea in 
vivo. TJN-950 was supposed to induce angiogenesis in both in 
vitro and in vivo models. 
uPA is a serine protease that regulates the blood coagula-
tion cascade, extracellular matrix degradation and remodel-
ing, angiogenesis, tumor invasion and repair of skin wounds 
[28-30]. uPAR is a highly glycosylated 55-65 kDa protein 
linked to the plasma membrane by glycosyl-phosphatidylino-
sitol [31], which is expressed in various types of cells including 
vascular endothelial cells [32]. Activation of pro-uPA to uPA 
occurs when pro-uPA is bound to its receptor, and the uPAR-
bound uPA is fully active at the cell surface [25,33-35]. The 
uPA-uPAR site, at which plasmin is efficiently generated, may 
provide a target for the treatment of inflammatory disorders, 
tumor invasion/metastasis, and angiogenic diseases [36]. The 
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